Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: A randomized, double-blind, placebo-controlled trial

Journal of Asthma and Allergy

Volumn 4, Issue , 2011, Pages 27-35

  Marmouz, Farid ^a   Giralt, Josep ^b   Izquierdo, Iñaki ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b J Uriach y Compania   (Spain)

Author keywords

Allergic rhinitis; Antihistamines; Circadian rhythm; Morning and evening symptoms; Rupatadine

Indexed keywords

EID: 84980331073     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S18265     Document Type: Article

References (20)

1. Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol. 2004;114(Suppl): S146–S153.
2. Haye R, Høye K, Berg O, et al. Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study. Clin Mol Allergy. 2005;3:1–6.
3. Aoyagi M, Watanabe H, Sekine K, et al. Circadian variation in nasal reactivity in children with allergic rhinitis: correlation with the activity of eosinophils and basophilic cells. Int Arch Allergy Immunol. 1999; 120(Suppl 1):95–99.
4. Brunton SA. Allergy management strategies: An update. Patient Care. 2002;Spring (Suppl):16–25.
5. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997;280(1):114–121.
6. Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63(Suppl 87):5–28
7. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67:457–474.
8. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86): 8–160.
9. Smolensky NH, Reinberg A, Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Inmunol. 1995;95:1084–1096.
10. Schenkel E. Effect of desloratadine on the control of morning symtomps in patients with seasonal and perennial allergic rhinitis. Allergy Asthma. 2006;Proc 27:465–472.
11. Binder E, Holopainen E, Malmberg H, Salo O. Anamnestic data in allergic rhinitis. Allergy. 1982;37:389–396.
12. Horak F. Impact and modulation of nasal obstruction. Allergy. 2002; 57(Suppl 75):25–28.
13. Valero A, Serrano C, Bartrá J, et al. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. Investig Allergol Clin Immunol. 2009;19:488–493.
14. Stübner P, Horak F, Zieglmayer R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2006; 96:37–44.
15. Meltzer EO. Does rhinitis compromise nigh-time sleep and daytime productivity? Clin Exp Allergy Rev. 2002;2:67–72.
16. Reinberg A, Gervais P, Ugolini C, et al. A multicentric chronotherapeutic study of mequitazine in allergic rhinitis. Annu Rev Chronopharmacology. 1985;3:441–444.
17. Hidmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy. 1999;29:133–142.
18. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Inmunol. 2003;111(Suppl): S835–S842.
19. Church MK, Maurer M, Simons FER, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65: 459–466.
20. Bousquet J, Bachert C, Canonica GW, et al. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy. 2009;64: 1516–1523.